Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...
Recent analyses show that Omicron variants of SARS-CoV-2 more strongly suppress major histocompatibility complex class I expression than previous versions of the virus. Throughout the pandemic, the ...
Controlling infectious diseases—especially zoonoses—is critical for both the economy and public health. Developing safe, effective vaccines remains the most reliable strategy for disease control, but ...
Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.
A new study published on the preprint server bioRxiv* analyzed the mechanisms by which two SARS-CoV-2 accessory proteins, ORF3a and ORF7a, can downregulate the expression of major histocompatibility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results